Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
6.7 EUR | +0.15% |
|
+5.18% | +20.18% |
08:30am | Mib up; wait for Powell hearing | AN |
Jul. 08 | Indices flat in Europe; banks do well in Milan | AN |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- With a 2024 P/E ratio at 30.83 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 3.27 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.18% | 1.27B | B | ||
+10.16% | 28.08B | B+ | ||
+25.93% | 2.46B | B | ||
+16.57% | 2.43B | - | A- | |
-49.01% | 2.23B | B- | ||
+33.33% | 2.02B | B | ||
-33.88% | 1.98B | C+ | ||
-24.65% | 1.58B | - | ||
+10.12% | 1.35B | - | ||
+34.05% | 1.33B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GVS Stock
- Ratings GVS S.p.A.